Piper Sandler Raises Labcorp Price Target $30 to $300, Eyes PathAI Collaboration
Piper Sandler raised Labcorp’s price target by $30 to $300 while maintaining a Neutral rating. Labcorp also partnered with PathAI to deploy the FDA-cleared AISight Dx1 digital pathology platform to boost diagnostic efficiency.
1. Analyst Rating and Price Target Change
Piper Sandler adjusted Labcorp’s rating to Neutral and lifted its price target from $270 to $300, signaling confidence in the company’s medium-term outlook but recommending a hold. The $30 increase reflects expectations for stronger revenue contributions from current service lines and new product integration.
2. PathAI Collaboration Details
Labcorp’s partnership with PathAI centers on deploying the FDA-cleared AISight Dx1 platform across its digital pathology labs. This cloud-based solution enables pathologists to manage slides digitally and apply AI-driven diagnostics, aiming to reduce turnaround times and enhance diagnostic accuracy.
3. Market Impact and Growth Prospects
The combined analyst upgrade and AI collaboration could strengthen Labcorp’s competitive position in diagnostic services by improving operational efficiency and patient outcomes. If the AISight Dx1 rollout accelerates adoption, it may support revenue growth and justify the higher price target over the next 12 to 18 months.